Profile data is unavailable for this security.
About the company
Bristol-Myers Squibb Company is a biopharmaceutical company engaged in the discovery, development and delivering advanced medicines that help patients prevail over serious diseases. It offers products for various therapeutic classes, which includes oncology, hematology, immunology, cardiovascular and neuroscience. Its pharmaceutical products include chemically synthesized or small molecule drugs, products produced from biological processes, called biologics and chimeric antigen receptor (CAR-T) cell therapies. Small molecule drugs are typically administered orally in the form of a tablet or capsule, although other drug delivery mechanisms are used as well. Biologics are administered to patients through injections or by intravenous infusion. Its in-line products include Eliquis, Opdivo, Orencia, Pomalyst/Imnovid, Yervoy, Sprycel, Reblozyl, Opdualag, Abecma, Zeposia, and others. The Company's product pipeline includes Krazati, MRTX1719, RYZ101, KarXT, ORM-6151, and Repotrectinib.
- Revenue in USD (TTM)47.44bn
- Net income in USD-7.26bn
- Incorporated1933
- Employees34.10k
- LocationBristol-Myers Squibb CoRoute 206 And Province Line RoadPRINCETON 08543United StatesUSA
- Phone+1 (609) 252-4621
- Fax+1 (302) 655-5049
- Websitehttps://www.bms.com/
Mergers & acquisitions
| Acquired company | BMY:NYQ since announced | Transaction value |
|---|---|---|
| RayzeBio Inc | 12.12% | 4.21bn |
| Karuna Therapeutics Inc | 14.37% | 14.40bn |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alnylam Pharmaceuticals, Inc. | 2.09bn | -332.26m | 31.83bn | 2.10k | -- | 982.81 | -- | 15.20 | -2.62 | -2.62 | 16.52 | 0.2511 | 0.5208 | 3.57 | 8.41 | 997,521.40 | -8.26 | -26.56 | -11.31 | -32.77 | 85.37 | 83.66 | -15.86 | -94.26 | 2.69 | -1.36 | 0.9694 | -- | 76.23 | 89.45 | 61.08 | -- | -13.29 | -- |
| Zoetis Inc | 9.15bn | 2.43bn | 79.73bn | 14.10k | 33.22 | 15.25 | 27.14 | 8.71 | 5.32 | 5.32 | 20.02 | 11.59 | 0.6431 | 1.06 | 6.86 | 649,078.00 | 17.13 | 14.47 | 19.38 | 17.18 | 70.13 | 69.77 | 26.64 | 25.77 | 2.27 | 18.96 | 0.5567 | 26.89 | 5.74 | 7.96 | 10.88 | 11.13 | 16.71 | 24.37 |
| Gilead Sciences, Inc. | 28.30bn | 126.00m | 111.86bn | 18.00k | 1,068.70 | 6.05 | 38.87 | 3.95 | 0.084 | 0.084 | 22.61 | 14.83 | 0.4842 | 3.56 | 6.04 | 1,572,167.00 | 0.1933 | 6.74 | 0.242 | 8.12 | 77.80 | 79.14 | 0.3993 | 16.95 | 1.10 | 17.00 | 0.5584 | 81.22 | -0.6048 | 4.15 | 23.37 | 0.7436 | -8.74 | 5.64 |
| Bristol-Myers Squibb Co | 47.44bn | -7.26bn | 118.10bn | 34.10k | -- | 6.89 | 40.21 | 2.49 | -3.60 | -3.60 | 23.38 | 8.45 | 0.513 | 3.97 | 5.12 | 1,391,056.00 | -7.84 | 3.05 | -10.45 | 3.76 | 75.87 | 76.13 | -15.28 | 7.69 | 1.09 | 11.30 | 0.7431 | 133.63 | -2.50 | 14.81 | 26.84 | 10.03 | 4.92 | 7.34 |
| Pfizer Inc | 60.11bn | 4.27bn | 142.41bn | 88.00k | 33.79 | 1.54 | 12.72 | 2.37 | 0.7438 | 0.7399 | 10.57 | 16.29 | 0.2767 | 1.60 | 4.71 | 683,079.60 | 1.98 | 8.20 | 2.39 | 10.40 | 70.82 | 69.34 | 7.16 | 22.68 | 0.729 | -- | 0.4225 | 60.11 | -41.70 | 7.46 | -93.20 | -7.94 | 12.21 | 3.82 |
| Amgen Inc | 32.53bn | 4.23bn | 155.83bn | 26.70k | 37.09 | 20.70 | 15.89 | 4.79 | 7.82 | 7.82 | 60.33 | 14.00 | 0.3587 | 2.08 | 4.83 | 1,218,502.00 | 4.66 | 10.36 | 5.87 | 13.06 | 60.48 | 75.41 | 13.00 | 26.51 | 0.9553 | 2.62 | 0.8892 | 59.54 | 7.09 | 3.49 | 2.52 | -4.36 | 8.54 | 10.04 |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 30 Sep 2024 | 179.05m | 8.83% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 104.47m | 5.15% |
| SSgA Funds Management, Inc.as of 30 Sep 2024 | 92.90m | 4.58% |
| Charles Schwab Investment Management, Inc.as of 30 Sep 2024 | 61.03m | 3.01% |
| JPMorgan Investment Management, Inc.as of 30 Sep 2024 | 50.39m | 2.49% |
| Geode Capital Management LLCas of 30 Sep 2024 | 43.20m | 2.13% |
| Capital Research & Management Co. (International Investors)as of 30 Sep 2024 | 42.65m | 2.10% |
| Norges Bank Investment Managementas of 30 Jun 2024 | 32.59m | 1.61% |
| PRIMECAP Management Co.as of 30 Sep 2024 | 23.37m | 1.15% |
| Fidelity Management & Research Co. LLCas of 30 Sep 2024 | 20.36m | 1.00% |
